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ABSTRACT 
The purpose of this study was to measure physiological and psychophysical responses 
and cognitive performance of motion sickness (MS) susceptible individuals during 
exposure to a ship motion simulator. Further, this study investigated the effects of 
selected classes of anti-MS drugs in suppressing motion sickness induced effects upon 
physiological adaptations, psychophysical responses and cognitive performance. Thirteen 
healthy male and female volunteers were recruited to take part in this research (25.1 ± 2.3 
years, 79.2 ± 14.6 kg, 174.4 ± 12.1 em). Each participant ingested seven pharmaceutical 
preparations, 1 placebo and 6 anti-MS medications including Meclizine, Promethazine 
and Dexamphetamine, Promethazine and Caffeine, Dimenhydrinate, Scopolamine and 
Dexamphetamine and Chlorpheniramine prior to exposure to simulated ship motion on a 
6 degree of freedom motion base. Sessions lasted up to one hour or until subjective MS 
ratings forced a termination of the trial. Subjective evaluations of MS symptom onset 
were taken using Graybiel's Diagnostic Criteria for Grading the Severity of Acute 
Motion Sickness and a 7-Point nausea rating scale. Defence Research Development 
Canada's Sustained Operations task batteries were employed to measure cognitive 
performance and were administered every 1 0 minutes throughout the motion exposure. 
Physiological measures, including core body temperature and skin temperatures were 
sampled continuously throughout the trial at 1 second intervals. A repeated measures 
ANOV A revealed no statistically significant differences in the physiological responses, 
however there was a significant difference found in the 7 -point nausea scale rating 
evaluation of psychophysical responses. The placebo trial was significantly greater than 
any of the intervention trials. In addition to this significant difference, there were 
apparent rank order tendencies in response to the placebo and drug interventions. From 
these data there are trends indicating some drugs are better used in some scenarios, such 
as those requiring cognitive awareness and performance, while other drugs may be 
applied in situations where the main purpose is for the comfort of the passenger, or of 
someone whom vigilance and alertness is not required. 
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1.0 INTRODUCTION 
Human performance has been shown to suffer decrements at the onset of motion sickness 
(MS) (Comperatore and Rivera, 1998). Thus it is important to prevent or mediate 
symptoms of MS in order to maximize performance efficiency and operator well-being. 
During a major NATO exercise in 1997, approximately one-half of 1025 naval subjects 
reported mild and moderate MS symptoms for sustained periods of time during 
operations in high seas (Colwell, 2000a). Those subjects in the group with mild and 
moderate MS symptoms reported substantially higher severity of problems with cognitive 
and physical performance, and with task completion than those with no MS symptoms. 
The types of problems reported and the potential consequences in terms of reduced 
operational effectiveness were sufficiently serious that it was suggested that these 
outcomes should be investigated further (Colwell, 2000b ). 
Motion sickness can present as a mild discomfort but can be severe and debilitating 
(Mcintosh, 1998). It can cause a decrease in motivation that in turn results in a lower 
work rate and therefore a disruption or abandonment of the task (Wertheim, 1998). The 
common symptoms include malaise, yawning, abdominal discomfort, pallor (Mcintosh, 
1998; Takeda & Morita, 2001 ), drowsiness, headache, stomach awareness, endocrine 
changes (Haward, 2000), sweating, nausea, vomiting (Haward, 2000; Mcintosh, 1998; 
Takeda & Morita, 2001) and cardiovascular changes such as tachycardia (Haward, 2000; 
Mcintosh, 1998). Postural hypotension can also be present during motion sickness with 
the change in blood volume due to blood pooling in the lower extremities (Mcintosh, 
1998). It has been reported that blood flow changes and inactivity associated with 
seasickness exacerbate the development of hypothermia (Nobel et al. , 2003). The 
underlying mechanisms responsible for core body cooling during bouts of MS are 
unknown and potential countermeasures for this additive effect on performance and 
survival require further investigation. 
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Intervention strategies, such as gazing upon an earth fixed reference, are often sought to 
mediate symptoms of MS (Bos et al., 2005). Most common are the use of pharmaceutical 
interventions to control MS symptoms. There are several classes of pharmaceutical 
medications on the market that can be consumed to aid in preventing the onset of motion 
sickness ( eg. antihistamines, anticholinergics ( antimuscarinic/antihistamines) and 
sympathomimetics). Medications are most effective when taken prior to exposure to the 
motion environment. Once vomiting occurs, it is near impossible for the oral medication 
to stay in the body long enough to penetrate the blood stream. 
Using medications such as scopolamine and Dramamine to mediate symptoms of motion 
sickness will often result in drowsiness and fatigue. Consequently stimulants are added 
to the medications in order to counteract the effect of drowsiness in the medications. 
While it is clear that optimal performance in command and control situations is critical, 
other related maritime demands may also be considered. Liferaft and lifeboat occupants 
can be exposed to a considerable amount of motion during evacuation and recovery 
situations. Experimental evidence indicates that a high percentage of liferaft occupants 
will experience severe symptoms of MS (MacKinnon et al., 2005). Training regimes 
should plan primary prevention strategies to manage liferaft passengers who might get 
MS during abandonment. Search and Rescue Technicians are also exposed to the same 
provocative conditions as those they are trying to rescue. Prevention of motion sickness 
while maintaining the ability to perform arduous physical tasks and maintain cognitive 
awareness and vigilance is of paramount importance to many. 
Leisure travelers and recreationalists who are exposed to provocative ship motions, car 
motions and air travel also face the potential performance decrements, and general 
malaise as a result of motion sickness. Arriving in an unfamiliar place and having to 
drive a vehicle while suffering from residual motions sickness symptoms after debarking 
a ferry or airplane can result in disastrous outcomes. 
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1.1 Objectives of Work 
The objectives of this work are to: 
1. measure physiological adaptations, psychophysical responses and cognitive 
performance of motion sickness susceptible individuals during exposure to a ship 
motion simulator. 
2. investigate the effects of selected classes of anti-motion sickness drugs in 
suppressing motion sickness induced effects upon physiological adaptations, 
psychophysical responses and cognitive performance 
1.2 Hypotheses 
The following null hypotheses were tested: 
H 1: Core body temperature will remain unchanged due to the onset of motion sickness or 
the introduction of anti-motion sickness medications 
H2: Skin temperature will remain unchanged due to the onset of motion sickness or the 
introduction of anti-motion sickness medications 
H3: Galvanic skin responses will remain unchanged due to the onset of motion sickness 
or the introduction of anti-motion sickness medications 
H4: Cognitive performance will remain unchanged due to the onset of motion sickness or 
the introduction of anti-motion sickness medications 
1.3 Assumptions and Limitations 
The following assumptions were made: 
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1. Although these research findings are intended to provide guidance to seagomg 
personnel, for the purposes of this research volunteer subjects were sampled from 
the general public, which included people from a range of employment status, 
socio-economic status and age that may not necessary reflect the demographics of 
working mariners. 
2. It remains difficult to recruit subjects who are susceptible to motion sickness. 
Those who are susceptible quite often refuse to volunteer for such studies. 
Furthermore, the protocol included seven repeated measurement sessions. A rectal 
probe was used to measure core body temperature. Many found this an invasive 
and perhaps embarrassing measurement to undergo, and may deter some from 
volunteering to participate, as was the case during recruitment in this study. 
Subjects were given detailed instructions regarding probe self-insertion and were 
enclosed in a comfortable and private room in order to perform this task. 
Recruitment strategies included a description of the research study and assurances 
that symptoms such as vomiting and retching would be avoided and was not the 
purpose of the study. With ethical approval by the University' s Human 
Investigations Committee, subjects were offered an honorarium for participating in 
the study. 
3. The motion conditions simulated in the experimental protocol were based on 
mathematical models of ship and water interactions. Scaling factors were used to 
accommodate the physical capacity of the ship motion simulator. 
4. One of the metrics required a self-report of MS symptoms being experienced by 
the subject. Familiarity with this scale would influence the quality of the reported 
score. Care was taken in explaining the MISC Scale. 
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2.0 REVIEW OF LITERATURE 
2.1 Prominent Contemporary Theories of Motion Sickness 
Since motion sickness was first identified, scientists and sufferers alike have been trying 
to understand causes and create theories to explain what it is and why it afflicts living 
beings. Early documentation attributed motion sickness to gastric upset, circulatory 
disturbance and various internal incongruencies (Reason and Brand, 1975). Early work 
supported the vestibular/proprioceptor theories that referred to vision, nervous system 
function, and muscle activity as the main sensory stimuli alerting the body to 
environmental changes and that influenced motion sickness. 
Reason and Brand (1975) developed a theory to explain their understanding of motion 
sickness based on a culmination of current views on motion sickness, the work they were 
doing, and expansion on what was happening in the field of research. This theory 
stimulated new approaches towards motion sickness research. Their sensory 
rearrangement theory consists ?f two main types of sensory rearrangement. The frrst is 
visual-vestibular; which indicates one type of motion from the eyes and another from the 
vestibular system (located in the inner ear), which is responsible for internal sense of 
balance. The second is canal-otolith; where the canals of the inner ear respond to rotation 
and the otoliths of the inner ear signal lateral translation. These are then further divided 
into two types of conflict. Type one conflict is when the two sensory systems relay 
opposing motion information, as in horizontal and vertical input, and type two is when 
one system signals motion, e.g. vertical, and the other system signals no motion (Reason 
and Brand, 1975). Another type of vestibular-proprioceptor rearrangement was added to 
the model as a third type of sensory rearrangement, which indicates a conflict between 
physical sensations of motion and internal information of motion (Guedry, 1991 ). 
Oman ( 1982) enhanced Reason and Brand's theory of sensory rearrangement by defining 
it with a mathematical formula. In his model, vectors are used to represent the change in 
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sensory information. This vector difference between perceived and actual movement 
grows as people become more susceptible to motion sickness, and symptoms grow more 
severe. 
The ecological theory of motion sickness and postural instability (Ricco and Staffrogen, 
1991 ), was developed after an extensive review of sensory conflict and sensory 
rearrangement theories. They discovered that " ... virtually all work in the area of motion 
sickness is motivated by a common set of fundamental assumptions. These assumptions 
find their most explicit expression in the sensory conflict view ... " (Ricco and Staffrogen, 
1991, p160). The sensory conflict theory, as they see it, indicates that there is something 
wrong with sensory stimulation; however they see sensory stimulation as equal in both 
provocative and non-provocative situations. They hypothesize that animals become sick 
in situations in which they do not have, or have not yet learned, strategies to maintain 
postural stability. They refer to the vestibular system's role in processing the 
environmental information to maintain stability and thus this theory, although with a 
fundamentally different paradigm to approach the study of motion sickness, has some 
crossover nonetheless, with the conflict theory. 
Bles et al. (1998) carefully reviewed Reason and Brand's sensory rearrangement theory 
and subsidiary theories (Guedry, 1991 ; Oman, 1982) to come up with a theory they 
believe incorporates all forms of sensory rearrangement into one type of conflict: "All 
situations which provoke motion sickness are characterized by a condition in which the 
sensed vertical, as determined on the basis of integrated information from the eyes, the 
vestibular system and the nonvestibular proprioceptors, is at variance with the subjective 
vertical as predicted on the basis of previous experience" (Bles et al. , 1998, p482). Bles 
and Bos (2006) later changed the term "subjective vertical" to "expected vertical" to 
better fit their theory. 
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The sensory rearrangement theory (Reason and Brand, 1975), and expanded upon by 
Oman (1982), Guedry (1991), Bles et al. (1998) is widely researched and supported and 
is the foundation of much of the research currently being done. The ecological theory of 
motion sickness and postural instability presented by Ricco and Staffrogen (1991) is 
relatively new and so has not been as extensively used in clinical experiments. These 
theoretical foundations allow researchers to further develop experimental conditions 
under which they may continue to explore the underlying causes of motion sickness. 
2.2 Types of Motion Sickness 
There are several types of motion sickness. Sea, car, air, space and simulator sickness are 
all common manifestations of the ailment that most persons are familiar. Although each 
form of motion sickness is similar, and can be sufficiently described using the sensory 
conflict theory, the provocative motion stimulus involved in each is unique. Motion 
sickness manifests in a number of symptoms regardless of the motion exposure causing 
the sickness. The commonly reported symptoms of motion sickness as described by 
Graybiel et al. (1968) are (in increasing severity) nausea, sweating, pallor, gastric 
discomfort and vomiting. 
Seasickness is likely the first form of motion sickness that was experienced by man 
(Griffin, 1991; Reason and Brand, 1975). The movement of a ship at sea can be an 
extremely provocative stimulus. The motions of waves can be unpredictable and severe 
for a long time, and the stimulus cannot be removed easily without returning to land 
(Reason and Brand, 1975). The contributions of roll, pitch and heave to seasickness were 
evaluated (Wertheim, Bos, and Bles, 1998). It was discovered that roll independently 
and roll and pitch combined both had slight motion sickness inducing effects, but were 
not as significant as the combination of all three. They found that even the addition of a 
small amount of heave significantly increases the provocative value of pitch and roll 
motion. This type of tri-axial stimulation, roll, pitch and heave, is unique in its 
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variability, and unlike other types of movement m common forms of terrestrial 
transportation. 
Carsickness in passengers is often related to travel experience (Gahlinger, 2000; Turner 
and Griffin, 1999). Youth tend to be more susceptible and incidence declines with age 
and travel experience (Reason and Brand, 1975). Other predominant factors in 
determining carsickness are the size of the visual field and the variability of car motions. 
A study evaluated visual field effects and motion sickness in cars (Griffin and Newman, 
2004). Ultimately, the findings showed that even a narrow view of the road ahead 
reduced sickness more so than even a real time video projection of the road ahead, 
possibly because of the movement of the camera. Subjects who were blindfolded or had 
no external view produced similar levels of sickness. The seating position of the subject 
was not found to be a factor contributing to motion sickness. 
Vogel, Kohlhaas, and Baumgarten (1982) examined the effect of linear acceleration in 
automobiles and motion sickness. They found that horizontal acceleration using multiple 
braking maneuvers is an effective motion sickness producing stimulus. Further, they 
found that acceleration in the backwards facing position was a more profound 
nauseogenic stimulus than the front facing position, including experiments that had 
subjects blindfolded. 
A large number of crew will experience airsickness at some point in their careers. Most 
often this will occur during training (Stott, 1990). The conflict that is experienced in 
airsickness is the effect of changing gravity when the aircraft is in turbulent conditions. 
Head movements made in turbulent conditions with changing gravity are not well 
tolerated in susceptible individuals (Bles et al. 1998). Kennedy et al. (1972) examined 
three types of aircraft penetrating a hurricane and the motion sickness provoking effects 
of the weather. Of the experienced crewmembers only one eventually experienced 
emesis. Of the twenty-one experienced crew members and the research team there were 
only two who experienced no symptoms. 
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Space sickness distinctly differs from other forms of motion sickness, as it is the 
expression of motion sickness symptoms in zero/micro gravity. Symptoms differ from 
motion sickness in conditions of normal gravity. Astronauts typically experience no 
sweating; flushing more so than pallor, and vomiting is sudden, without nausea. Non-
susceptibility occurs after three days when motion sickness symptoms disappear, maybe 
because of a lack of reference to down. Space sickness, like other forms of motion 
sickness, may well be attributed to the vestibular system receiving false information. 
Throughout weightless flight, external reference points do not correspond with sensory 
input causing a sensory conflict. There is some inconsistency as to what symptoms are 
typical in space sickness (Money, 1991 ). Little information is available regarding the 
severity of space sickness, likely due to of the lack of reported motion sick symptoms. 
The importance of the job and the requirement to be functioning at optimal levels is 
presumed to deter sufferers from accurately reporting illness (Money, 1991). Space 
sickness can have debilitating effects that are likely to reduce efficiency m an 
environment that does not tolerate error (Reason and Brand, 1975). 
Simulators are commonly used to reduce the cost and risk of training pilots and drivers 
(Money, 1991 ; Mourant and Thattacheny, 2000). Specific limitations of simulators are 
the ability to replicate actual movements, and the ability to reproduce an accurate visual 
scene. Visual simulators are known to produce symptoms of motion sickness because of 
poor representation of self-motion. That is, the eyes give the sense that the body is 
moving with the references given by the simulator, however, the body senses that it 
remains stationary (Kennedy et al. , 1990). Also, simulator users are finding that as 
technology improves the problem of motion sickness gets worse. Simulator sickness 
incidence varies and paradoxically, is most common among newer pilots with little 
experience on a simulator and pilots with more real life experience (Money, 1991). 
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2.3 Incidence and Predictors of Motion Sickness 
Within any situation it proves helpful to be able to predict an individual' s susceptibility to 
motion sickness stimuli. In experimental settings, screening subjects for motion sickness 
susceptibility with stringent criteria is crucial to describing the research sample. It is also 
crucial to some professional training programs to know in advance if it is worthwhile to 
expend the resources to train a fighter pilot, or an astronaut, before knowing whether the 
candidate can work reliably in motion-rich environments. 
There are a number of ways to assess an individual's susceptibility to nauseogemc 
stimuli. The range in feasibility and cost effectiveness of these assessments has resulted 
in fine-tuning personal history questionnaires, and developing mathematical formulas to 
predict motion sickness incidence in provocative motion situations. 
Assessment techniques include both actual exposure to motion and questionnaires. 
Motion exposure techniques subject the individual to accelerative stimuli and then grade 
susceptibility. The swing test and coriolis techniques (vestibular adroitness test, dial test, 
and the brief vestibular disorientation test) are well known actual exposure tests (Reason 
and Brand, 1975; Golding, 2006). 
Questionnaires take a tally of past motion experiences and their effect on the individual 
as rated by the severity of motion sickness symptoms. Reason and Brand (1975) 
developed a motion sickness susceptibility questionnaire (MSSQ) comprised of two 
sections, one to assess motion sickness events up to twelve years old, and one to assess 
the number of events in the last ten years. Administering questionnaires is timely and 
subjects are usually able to recall experiences easily, without the need to induce sickness. 
The most common problem with questionnaires is that groups who will be evaluated 
based on their scores (eg: pilots) may not always be truthful (Reason and Brand, 1975). 
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Golding (1998) reported that many subjects have not found the original Reason and 
Brand version of the MSSQ easy to complete without guidance and explanation. He 
developed a new MSSQ-Long to be more easily completed by subjects, and to simplify 
the scoring. The MSSQ-Long was tested over several pilot studies, and then later 
administered the test to a larger group of university students and to a group of patients 
undergoing chemotherapy. Ultimately, he found that the questionnaire was both easy to 
understand and complete by the subjects. As well the MSSQ-Long provided adult 
reference norms almost identical to those presented in the original MSSQ and the internal 
validity was high. Golding suggests that the revised MSSQ may be used as a direct 
replacement of the original (Golding 1998). 
Golding (2006) later revisited the MSSQ-Long and Reason and Brand's MSSQ (1975) to 
create a shorter questionnaire that would ultimately retain validity and speed-up 
evaluations. At eighteen questions, it is one-third the length of the MSSQ-Long (Golding 
2006). To condense the number of questions a repeated item analysis was conducted 
with various scoring methods. Technology based questions were removed as they 
showed little significance and vomiting-specific questions were removed. Both the 
MSSQ-Long and MSSQ-Short were administered to subjects exposed to provocative 
motion in a controlled laboratory setting. The predictive validity of the MSSQ-Short was 
comparable to the previous MSSQ-Long, with the only drawback being that the MSSQ-
Long had a higher predictive value for highly susceptible subjects (Golding 2006). 
Powell et al. (1962) tested a motion history questionnaire (MHQ) on all new recruits of 
the Royal Canadian Air Force (RCAF) in 1960-61. There were 151 recruits in the study 
and 14 of them failed (based on their scoring criteria) both the MHQ and the actual 
exposure airsickness test. They found the MHQ a significant measure approaching the 
p<0.01 level. They did not find the combination of MHQ and actual testing to be any 
better a predictor that the MHQ alone. It is interesting to note that, of these 14 who failed 
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the tests administered by Powell et al., five later failed out of RCAF training later due to 
motion sickness. 
O'Hanlon and McCauly (1974) developed an empirical method for predicting motion 
sickness incidence (MSI) by exposing subjects to single-frequency, sinusoidal, vertical 
motions (Colwell,1989) The model predicts MSI (%) using magnitude, frequency and 
duration of vertical accelerations. Using this formula in a situation that emulates the 
original study they fmd this a reasonable measure of MSI. 
2.4 Effects of Motion Sickness on Performance 
Implications of motion sickness on performance are of critical importance when 
executing rescue operations, operating commercial transport vehicles, when crew are 
performing tasks during motion, and maintairung the operation of a moving vehicle. 
Motion sickness may negatively impact both the physical ability as well as the cognitive 
function of those in passenger, crew and command positions. There is often low or no 
tolerance of error when operating spacecraft, marine vessels, or in mass transport. 
Evaluating the effects of the Command and Control environment on soldier health and 
performance observed a negative effect on the soldiers when they attended to computer 
screens while the vehicle was moving (Cowings et al. , 1999). Short breaks did not 
alleviate the decreases in performance, and mood and performance were both impaired in 
the vehicle. Malaise and drowsiness were among the most frequently reported symptoms 
of motion sickness and had a negative impact on the soldier' s operational efficiency. All 
24 soldiers reported symptoms of motion sickness, 55% of them were moderate to severe 
symptoms, and 15% of subjects experienced vomiting. 
The susceptibility to motion sickness was measured in crew operating three types of 
aircraft during hurricane penetration (Kennedy et al., 1972). Only two of 39 people 
involved in the study, including the subjects, the researchers, and the experienced 
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crewmembers did not expenence any symptoms of motion sickness, and they were 
experienced crew. The range of symptoms reported varied from mild to motion sick with 
vomiting. Of the individuals involved in the study, four experienced emesis and one was 
an experienced crewmember. In this study, the more severe the conditions were, the 
poorer the scores on the tests of performance were. Performance generally continued to 
deteriorate except in one type of aircraft, where performance began to improve when the 
aircraft began its return to the base, and these results may be partly attributed to 
habituation. 
Space motion sickness has been reported, however, it has been suggested that perhaps it 
is under-reported due to the intolerance of error and high expectation of performance 
during space missions (Reason and Brand, 1975). Kelly et al. (2005) evaluated 
crewmember performance before, during and after spaceflight. The only changes in 
performance were during spaceflight where response time during number recognition 
tasks and digit-symbol substitution increased. 
In a report by the US Coast Guard, Comperatore and Rivera (1998) evaluated crew 
fatigue and performance on coast guard cutters. Decrements were seen in the day-to-day 
testing where the researchers expected to see improvements due to a learning effect. The 
sea motion affected the motivation of the crew, although perceived motion discomfort 
was rated fairly low. Due to a perceived lack of anonymity during recruitment and 
testing within the military environment, military personnel fear that accurate subjective 
reporting in a negative manner may impact their job status, especially if they are 
reporting discomfort in their primary working environment, such as a sailor reporting 
motion sickness at sea. Therefore it is difficult to validate subjective reports, as 
sometimes subjective and objective reports will be at odds. Fatigue was a factor that 
influenced performance, and the mean fatigue rating throughout the testing period 
remained at about the level that suggested the crew were losing interest in staying awake 
(about 42 on a scale of 1-100, 1 being wide awake). 
20 
The effect that motion has on performance may also be related to the extent the task 
distracts the individual. Bos et al. (2005) evaluated the visual effects on motion sickness 
in a ship motion simulator. The effects of inside, outside and no view were evaluated, 
using performance on cognitive tasks as a measurement tool. Their findings indicated no 
differences between the groups that could not be attributed to the conditions of the 
experiment (i.e. the no view group used auditory tasks as opposed to visual tasks as in the 
inside and outside (fixed horizon) groups), however, reported symptoms of motion 
sickness decreased when subjects were blindfolded. Blindfolding removes all visual cues 
of motion, for example movement of a curtain or a pencil rolling gives a visual cue to the 
brain, which may be different from the proprioceptive cues of motion being 
communicated to the brain. Relying only on proprioceptive cues of motion removes the 
mismatch that is observed otherwise contributing to the development of motion sickness. 
Reason and Brand (1975) also suggested that task performance might abate motion 
sickness symptoms. 
There is a relationship between task performance and motion sickness symptoms. The 
magnitude of motion stimulus, the type of task and the level of comfort with both the task 
being performed and the surrounding environment all have a role in how severely or how 
detrimentally one may affect the other. In studies by Kennedy et al. (1972), Comperatore 
and Rivera (1998), and Cowings et al. (1999) perhaps the decrement in performance may 
be attributed to the onset of motion sickness prior to performance. Conversely in the 
study by Bos et al. (2005) the subjects are performing their tasks at the time motion 
sickness symptoms would be developing and in this case their cognitive preoccupation 
may impede these symptoms. 
2.5 Prevention and Treatment of Motion Sickness 
Preventing the onset of motion sickness symptoms is critical for both the operation of 
vehicles and enjoyment and ease of travel. There are dozens of medications to treat and 
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prevent motion sickness. Many of them are considered reliable and are repeatedly tested 
and measured alone, and in various combinations. While the underlying mechanisms of 
motion sickness are still in question, researchers experimenting with new drugs in the 
treatment of motion sickness are continually finding formulations which mediate or 
eliminate symptoms of motion sickness. 
Scopolamine (hyoscine) and d-amphetamine in combination are most frequently and 
effectively used as treatment (Wood et al. , 1990, Wood and Graybiel, 1970a Wood and 
Graybiel, 1970b, Wood et al. 1968). Promethazine is often the second drug of choice 
(Wood and Graybiel, 1970a; Wood et al., 1968; Wood and Graybiel, 1970b; Graybiel, 
1970), and is frequently used by NASA to treat space sickness (Yates, Miller, and Lucot, 
1998). 
Used to treat seasickness in a study by Holling, McArdle, and Trottter (1944), 
scopolamine was found to be an effective dose at 0.6 mg, whereas at 1.2 mg the subjects 
complained of dry mouth, although they were not drowsy. However, in a study 
comparing seven commonly used anti-motion sickness drugs on the prevention of 
seasickness, Schmid et al. (1994) found that the subjects using scopolamine on its own 
have a tendency to more illness than the other treatment groups. A study of the effects 
oftransdermal scopolamine at 12 and 72 hours after administration showed mixed results 
(Graybiel et al., 1982). The first application resulted in four beneficial responses after 12 
hours and none after 72, where in the second application there were four beneficial 
responses after 12 hours and three after 72. One subject experienced severe side effects 
that did not diminish after the 72 hours. The variability in these results are attributed to 
the possibility of poor functioning of the transdermal patch system and temperature, 
indicating more effective absorption in warmer weather. Nachum et al. (2006) support 
the use of transdermal scopolamine use for long duration travel (6 hours or longer) 
especially when oral doses may not be effective, or tolerable. 
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Wood et al. (1965) evaluated nine anti-motion sickness drugs using the Slow Rotation 
Room. Their findings showed that scopolamine increased the subjects' average tolerance 
to the stimulation by 147% compared to placebo, and d-amphetamine increased tolerance 
by 70% as compared to placebo when used alone. When scopolamine and d-
amphetamine were used in combination, Wood et al. observed an increase of 194% in 
tolerance to the stimulation. 
Another study by Wood and Graybiel ( 1968) using the Pensacola Slow Rotation Room 
evaluated the effectiveness of 16 anti-motion sickness drugs. The drugs tested fell into 
four categories: sympatholytic, antihistamines, sympathomimetic and parasympatholytic. 
Their fmdings were very clear indicating that combinations of sympathomimetic 
(amphetamine) and parasympatholytic (scopolamine) drugs are significantly more 
effective in treating all symptoms of motion sickness including nearly eliminating side 
effects such as drowsiness and dry mouth at the 0.6mg scopolamine and 10 mg 
amphetamine dose. 
Based on the fmdings by Wood and Graybiel (1968), a new understanding of the 
mechanisms involved in the development of motion sickness was proposed (Wood and 
Graybiel, 1970). They suggested that competing neural systems, one activated by 
acetylcholine and one by norepinepherine, might be involved in motion sickness. This 
idea was reiterated when evaluating the effects of anti-motion sickness medications on 
secondary symptoms of motion sickness (Wood et al., 1990). Long after nausea and 
vomiting have subsided secondary symptoms negatively affect performance, cause 
drowsiness and slow brain waves. Based on the results of the evaluation of anti-motion 
sickness medications on secondary symptoms, Wood et al. (1990) hold that the 
combination of scopolamine and amphetamine is the most effective in treating both 
nausea and vomiting, as well as treating the secondary symptoms of motion sickness. 
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Antihistamines such as promethazine 25 mg, diphenidol 50mg and dimenahydrate 50 mg 
(Dramamine) ranked next to sympathomimetic, and parasympatholytic drugs in 
effectiveness (Wood and Graybiel, 1968). Though not as effective as other drug classes, 
they have a longer protective duration and are safer (Yates et al., 1998; Wood and 
Graybiel, 1970). A study by Strickland and Hahn (1949) found that Dramamine 
prevented airsickness in 71.3% of 108 subjects, compared to 44.4% when administered a 
placebo. Schmid et al., (1994) studied the effects of seven commonly used drugs to 
prevent seasickness. Their findings showed that dimenahydrate 50mg combined with 
caffeine 50mg (Dramamine) was the most effective in preventing motion sickness 
symptoms, and cinnarizine 20mg combined with domperidone 15mg (Touristil) a close 
second. 
Aside from the resounding support for several effective pharmacological treatments for 
symptoms of motion sickness, there are also alternatives being explored. A study of 24 
healthy subjects exposed to Coriolis stimulation evaluated controlled breathing and 
listening to a music audiotape to control motion sickness symptoms (Sang et al., 2003). 
Compared to the no intervention group both controlled breathing and listening to music 
delayed the onset of mild nausea. Although these methods are only half as effective as 
drugs at increasing tolerance to provocative stimulus they note the benefits of these 
methods being free of side effects, inexpensive and easy to implement. Ginger has also 
been used for subsiding motion sickness related nausea, possibly by preventing gastric 
dysrhythmias (Lien et al., 2003; Ernst and Pittler, 2000). Schmid et al. (1994) found 
ginger (250mg) to be equally as effective in preventing motion sickness as cinnarizine 
(25mg). 
There are several treatments shown to be effective to delay or treat motion sickness 
symptoms, both pharmacological and otherwise. The evidence shows that any of these 
measures will increase resistance to stimulation over using no treatment at all. For the 
lay traveler choosing an inexpensive, over the counter drug may be a quick fix for their 
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discomfort, but the solution is not so clear for those who are in command of the vehicle 
or vessel. Often, habituation occurs after repeated exposure to similar types of 
provocative motion (i.e.: new pilots or crew on a ship will become accustomed to the 
motions and they will no longer be motion sick inducing). In very few cases motion 
sickness never subsides, and in these individuals appropriate treatment must be found, or 
they may end their career. The severity of symptoms versus the side effects of drugs 
must be carefully weighed when they are treating symptoms of motion sickness for 
individuals in command or control positions. 
2.6 Gaps in the Literature 
Motion sickness has been explored in many ways using both actual and simulated motion 
expenences. How performance is maintained during the motion exposure has been 
researched under various operational or experimental conditions, little research has 
examined the effects of various mediating pharmaceuticals in a well controlled motion 
environment. Similarly, examining the effects of moderate motion sickness on 
physiological and psychophysical responses remains limited. This research contributes to 
this gap in the current literature. 
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3.0METHODS 
3.1 Subjects 
Thirteen apparently healthy male (8) and female (5) volunteers (25.1 ± 2.3 years of age, 
79.2 ± 14.6 kg, 174.4 ± 12.1 em) were recruited to participate in this study. Participants 
were recruited by posters (Appendix A), various electronic media, and by word of mouth. 
This study was granted ethical approval from MUN HIC. 
Participants were given a written copy of the protocol and a verbal explanation of the 
experiment, including the expectations of the subject, the roles of the investigator and the 
participant' s right to voluntarily withdraw from the experiment at any time. Participants 
were fully informed of the purpose, details, discomforts and risks associated with the 
experimental protocol before being asked for their written informed consent. The risks 
and discomforts included self-insertion of a rectal thermometer, motion sickness 
symptoms elicited by the ship motion simulator, exposure to cold and side effects from 
the experimental interventions, such as drowsiness. Volunteers who agreed to participate 
were required to read, understand, discuss and agree with the subject consent form 
(Appendix B) and the invasive medical procedures consent form (Appendix C) per 
Memorial University of Newfoundland Human Investigations Committee (MUN HIC) 
guidelines, and to signify this agreement by signing these consent forms. In order to 
participate, all volunteers were required to be in good general health, with no known 
history of vestibular or occulomotor disease. Health status was screened using a Medical 
History Questionnaire (Appendix D). This study was granted ethical approval from 
MUNHIC. 
Volunteers who were deemed healthy and able to participate were further screened for 
susceptibility to motion sickness. In the present study recruitment was a difficult task, 
asking for a large time commitment over an extended period, and the experimental 
conditions asked that subjects voluntarily subject themselves to undesirable conditions 
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(moderate cold environment, sickness potential, probes and sensors). Based on these 
factors, subjects with high susceptibility for motion sickness needed to be selected. 
Each subject completed the Motion Sickness Susceptibility Questionnaire (Appendix E) 
to determine their susceptibility to motion sickness. The mean MSSQ score was 127 
(±43.2, min 63.9, max 217.4). Golding and Kergueulen (1992) suggested that a score of 
68.9 corresponded to a person that was more susceptible than would be expected from the 
normal population. 
Participants were asked to maintain normal daily activities, consume a light meal prior to 
each trial and to refrain from alcohol and the use of cold and allergy medications (such as 
antihistamines, antimuscarinic and anticholinergic drugs) for 36 hours before each 
experimental session. Participants were asked to inform the researcher of any changes in 
health status since their initial assessment; including but not limited to viral illnesses, new 
prescription or "over-the-counter" drugs, and new risk of pregnancy within a week of the 
actual experiment. 
3.2 Experimental Design 
3.2.1 Anti-Nauseant Medications 
A randomized double-blind repeated-measures protocol was used to assess the impact of 
the anti-nauseant medications upon both physiological responses and psychomotor 
performance. All participants participatetl in 7 trials with at least a 7-day washout period 
in between trials. Data collection occurred at the same time of day, on the same day of 
the week for each subject. The participants ingested one of 6 anti-motion sickness drugs 
and a placebo prior to exposure to the simulated motions. The researcher verified that 
participants ingested the designated medication two hours prior to arriving at the Centre 
for Marine Simulation (CMS) for the data collection session. 
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The anti-motion sickness drugs and their characteristics are listed in Table 3.1 and are 
available for personal use through a physician's prescription. The test doses are standard 
clinical amounts. All formulations prescriptions were provided by the Defence and 
Research Development Canada - Toronto. In order to maintain the double blind protocol 
of this study, all medications were prepared in identical capsule format by a contracted 
pharmacy (Central Medical Pharmacy, Toronto, ON, Canada). This company maintained 
the coded drug information until release to the experimenters following the completion of 
the data collection portion of the study. 
3.2.2 Motion Simulator 
The study was performed in the Ship Motion Simulator (SMS) of the Centre for Marine 
Simulation (CMS), at the Marine Institute of MUN. This facility is a large ship bridge 
(5m x 7m), mounted upon a six degrees of freedom motion base, and surrounded by 360° 
azimuth coverage by visual projection screens (Figure 3.1). 
Figure 3.1: Ship Motion Simulator 
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Table 3.1: Name and description of drugs employed in study. 
Drugs and dosage Optimal effect Known side Known drug 
time effects interactions 
Meclizine (Bonamine®) Acting 2 hours Drowsiness, Increased CNS 
50 mg,Antiemetic (MEC) after ingestion, dry mouth, depression with 
effects lasting 8-12 fatigue other CNS 
hours depressants 
Promethazine 25 Mg + Acting 2 hours Drowsiness Increased 
dexamphetamine 10 mg, after ingestion, drowsiness with 
Antihistamine effects lasting 8-12 antihistamines 
(PROM+DEX) hours 
Promethazine 25 mg + Acting 2 hours Drowsiness Increased 
caffeine 200 mg, after ingestion, drowsiness with 
Antihistamine effects lasting 8-12 antihistamines 
(PROM+CAF) hours 
Dimenhydrinate Acting 2 hours Drowsiness, Increased 
(Gravol®) 50 mg, after ingestion, dry mouth drowsiness with 
Antihistamine (DIM) effects lasting 8-12 antihistamines 
hours 
Scopolamine 0.8 mg + Acting within 30- Drowsiness, 
dexamphetamine 5 mg, 60 min after dry mouth 
anticholinergic ingestion, effects 
(SCOP+DEX) lasting for about 4 
hours 
Chlorpheniramine (12 About 3 hours Drowsiness Increased 
mg), Antihistamine after ingestion, and dry drowsiness with 
(CHL) effects lasting for mouth antihistamines 
about 5 hours 
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The SMS produces motions for a real-time ship simulation. The key variables are the size 
and shape of the hull, the ship speed and course, the wave height, wave period (or wave 
length) and wave direction. The motions for the experiment were developed for a relative 
wave direction of approximately 45° off the bow, and with a frequency of vertical motion 
of approximately 0.2 Hz. The ship motion simulator being used for the experiment has 
both software and hardware safety interlocks to prevent loss of control and to avoid 
excessive motions. This facility is ISO 9001 certified, and it has a safe operating history 
of over ten years use as a motion platform for research projects and maritime certification 
programs delivered by the Marine Institute ofMUN. 
The subject placement was standardized within the simulator cabin (see Figure 3.2). A 
chair and desk were placed on the left wing of the bridge. Non-slip pads were placed 
beneath the desk legs and chair legs to prevent sliding during the motion. Researchers at 
MUN have used this set-up previously, and motions provide no threat for extreme subject 
instability (Colwell and MacKinnon, 2007, Bos et al., 2005). 
The internal cabin temperature of the simulator was maintained at 10 ± 0.5°C. A 
temperature sensor was employed to ensure a stable internal cabin temperature was 
maintained throughout the data collection period and across each trial. 
Figure 3.2: Subject placement in the SMS 
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3.2.3 Physiological Measurements 
Upon arrival at the Center for Marine Simulation (CMS) the participant was prepared for 
each data collection trial. Rectal temperature was measured using a Philips 400 series 
thermistor (model 21 090A, Philips Medical Systems) subject-inserted 15cm into the 
rectum. Each subject had been previously briefed on how to self-perform this procedure 
(see Appendix F) and to have the subject assure that the insertion was done to a specified 
depth. The subject then dressed in shorts, shirt, socks and comfortable shoes and 
presented themselves to the investigator. The investigator applied the skin temperature 
sensors (SA1-RTD surface temperature sensor, Omega Engineering, Inc. Stamford, CT.) 
to seven sites (Hardy and Dubois, 1938): forehead, deltoid, hand, abdomen, upper 
anterior thigh, shin, and foot. Refer to Table 3.2 for description of anatomical landmarks 
used to position sensors. 
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Table 3.2: Table of anatomical landmarks for placement of skin temperature sensors. 
Location Anatomical Landmarks Weighted values 
(Hardy and Dubois, 
1938) 
Forehead Half-way between eyebrows and hairline, centered 0.07 
between the eyes 
Deltoid In the centre of the deltoid on the lateral aspect of the 0.14 
arm. 
Hand Posterior, 2.5 em from the wrist, centered over the 0.05 
metacarpals. 
Abdomen Scm to the left of the omphali on 0.35f 
Upper Midway between the inguinal fold and the superior 0.19 
anterior border of the patella 
thigh 
Shin Midway between the talocrural joint and the superior 0.13 
point of the tibia 
Foot On the dorsal surface, centered over the metatarsals 0.07 
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The investigator then secured the galvanic skin response (GSR) electrodes (S220 
Galvanic Skin Response Sensor, Qubit Systems, Kingston, ON) to the index and middle 
fingers of the non-dominant hand and measured change in sweat gland activity, a 
response of the sympathetic nervous system (see Figure 3.3). 
Figure 3.3: Galvanic Skin Response setup 
The time-histories for each physiological variable were collected throughout the data 
collection period. The analogue signal for each physiological measure was sampled at 2 
Hz then converted via an analogue to digital converters and stored on a computer for later 
analyses. 
3.2.4 Psychomotor Measurements 
Prior to commencement of the study, all subjects underwent an habituation period to 
familiarize themselves with the nature of the psychomotor tests (DRDC Toronto 
Sustained Operations (SUSOPS) package). This was to ensure that a learning effect was 
not being measured in the subsequent experimental trials. The investigator confirmed 
with each participant that slhe understood the demands of the SUSOPS tasks. 
The battery of SUSOPS tests completed as a baseline measure and during specific 
intervals during the motion exposure took three minutes to complete. During motion 
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exposure the tests were performed at ten-minute intervals starting at minute seven. The 
computer-based Cognitive Test Battery combines three tests from the DRDC Toronto 
Sustained Operations (SUSOPS) package. The test battery employed in this study 
included I minute each of serial reaction time (SRT), logical reasoning task (LRT), serial 
subtraction task (SUB) tests. 
The SRT task displays a four key keypad with a different character or symbol on each 
key. One of the four graphics will be shown in a display area and the subject must click 
on the corresponding key as quickly as possible. Display characters are selected from the 
four-keypad characters randomly with replacement. Since this allows for sequential 
repetition of a character, the display colors are reversed from presentation to presentation 
so that the subject can detect the onset of a new stimulus (Pen SUSOPS Help File, 2008). 
In the SUB test, the subject is presented with an initial subtraction problem. The 
subtrahend is in the range of 500-999, and the minuend is in the range 5-9. The subject 
continuously subtracts the fixed minuend from their most recent result, starting with an 
assigned subtrahend. The subject enters their answer by clicking on a numeric keypad or 
pressing the corresponding keys on the keyboard. No further input is accepted after the 
specified duration has elapsed (Pen SUSOPS Help File, 2008). 
The LRT presents a series of problems concerning the relationship between two entities, 
A and B. A proposition is displayed in the form; entity relationship other-entity. 
Examples would be A precedes B, and B is not followed by A. The proposition is 
followed by a statement in the form "AB" or "BA" and the subject responds by clicking 
on either the TRUE or FALSE button. Propositions and statements are displayed 
concurrently. The task continues until the specified duration elapses (Pen SUSOPS Help 
File, 2008). 
34 
3.2.5 Subjective Quantification of Motion Sickness 
Subjects reported symptoms of motion sickness based on the 7-point nausea rating scale 
(see Table 3.3) at regular, 2-minute intervals, which was reduced to 1-minute intervals as 
the subjects approached the defined experimental termination score of 6 or if the core 
body temperature approached 35°C. Subjects were also encouraged to report their 
symptoms (e.g. stomach awareness, nausea, headache). Participants also reported 
subjective drowsiness and cold comfort levels. 
Subjects also reported pre- and post-motion symptoms according to Graybiel ' s 
Diagnostic Criteria for Grading the Severity of Acute Motion Sickness (Table 3.4). 
Symptoms pre-and post-motion exposures were graded using this scoring chart, which 
gave a quantitative value to symptoms based on their severity. The diagnostic tool for 
grading motion sickness severity is largely used by the investigator to evaluate the 
subject's motion sickness. Pallor and sweating (as observed by the investigator) and 
nausea (as reported by the subject) are allocated a severity score. Points are given for 
each symptom/severity reported or observed and the total Graybiel score is calculated. 
The final Graybiel score was the calculated difference between post- and pre-motion 
scores (Graybiel et al., 1968). 
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Table 3.3: The 7-point Nausea Rating Scale (Golding and Kerguelen, 1992) 
Rating 
0 
1 
2 
3 
4 
5 
6 
Definition 
No Symptoms 
Any unpleasant symptoms, however slight 
Mild unpleasant symptoms (stomach awareness, sweating but no 
nausea) 
Mild nausea 
Mild to moderate nausea 
Moderate nausea but can continue 
Moderate nausea, want to stop 
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Table 3. 4:Graybie/ 's diagnostic criteria for grading the severity of acute motion sickness. (Graybie/ et a/., 
1968). 
Category Pathogonomic Major Minor Minimal QS 
16 Points 8 Points 4 Points 2 Points 1 Point 
Nausea Vomiting I Nausea Nausea I Epigastric Epigastric 
Symptom Retching II/III Discomfort Awareness 
Skin Pallor III Pallor II Pallor I Flushing/ 
Subjective 
Warmth/ 
Red Face 
Cold III II I 
Sweating 
Increased III II I 
Salivation 
Drowsiness III II I 
Pain Persistent 
Headache 
CNS Dizziness-
Eyes closed 
II, Eyes 
Open III 
The original sources of the 7-Point Nausea Rating Scale (Golding and Kerguelen, 1992) 
and Graybiel 's diagnostic criteria for grading the severity of acute motion sickness 
(Graybiel et al., 1968) did not report either reliability or validity coefficients for their 
respective scales. However, Graybiel et al. (1968) reported that reliability and validity of 
the diagnostic criteria was demonstrated by evaluating the effectiveness of anti-motion 
sickness drugs using a double-blind experimental technique. 
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3.2.6 Data Collection Protocol 
The duration of each trial lasted approximately an hour and a half, including the 
preparation of subjects, baseline, and exposure to motion (lasting a maximum of one 
hour). The parameters being monitored and collected during this period were surface 
skin temperature, core body temperature, galvanic skin response, and psychomotor 
performance measures using the SUSOPS task battery and subjective nausea rating 
scores. 
Figure 3.4 represents the timeline of events beginning with subject preparation, through 
baseline measurement, and the sequence of events corresponding to each data collection 
interval for each trial. 
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Figure 3.4: Timeline of events during trial. This timeline is subject dependent. Each endpoint was 
determined by voluntary withdrawal, determined by reaching a maximum nausea score (6), or completion 
of the 60-minute trial. The colours denote the variables collected at the indicated minute indicated on the 
x-axis. 
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3.3 Statistical Analysis 
The perceptual, physiological and psychomotor data were analyzed by repeated measures 
ANOVA using SPSS (vll.O) software. This examined the difference in scores from the 
baseline (pre-motion) measure and the final ( post-motion) recorded or reported score 
across the seven conditions (6 drugs and a placebo). A two-way ANOVA considering the 
effects of medication and time series was not employed because of the large variability in 
trial duration. That is, in some cases the subject may have gone the full 60-minutes of 
exposure or in some cases only lasted 14-minutes. Given the small sample-size and the 
methodological approach inherently creates opportunities for considerable data loss over 
time. A Tukey's LSD post hoc test was identified to be used if there were differences 
found between main factor effects. 
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4.0 RESULTS 
4.1 Introduction 
This chapter reports the results of the perceptual, physiological and psychomotor 
measures recorded during the experimental trials. Table 4.1 reports the total time of 
motion exposure and the maximum 7-point nausea rating score (in brackets) achieved by 
each subject for each experimental condition. Mean values are reported in subsequent 
sections that report the statistical analyses of these variables. 
4.2 Results of Psychophysical Data Collection 
Statistical analyses of the data collected during the experimental trials were conducted 
using a series one-way ANOV A. In all cases, no statistical differences were observed for 
the main effect medication. Reasons for not detecting significant difference are discussed 
later in the Discussion chapter. However, for archival purposes, the mean, standard 
deviation (SD) and coefficient of variation (CV) for each experimental variable are 
reported. Furthermore, the percent change from the value measured during the "placebo" 
trial is calculated for each parameter. Using this percent change value, the differences 
from the placebo were put in a rank order. This approach allows for a qualitative 
assessment for similarities between the different drug conditions. Graybiel et al. ( 1968) 
suggested that it was possible to rank the different drugs (or combination of drugs) by 
their relative effectiveness in order to determine whether there were trends in their 
principle pharmaceutical actions. 
4.2.1 Duration of Trial 
Statistical analysis of trial duration per treatment condition was tested using repeated 
measures ANOV A. The results of the ANOV A indicated there was no significant 
difference found between the trial duration of each treatment condition 
(F6,I2=0.815;p=0.590). These data are reported in Table 4.2. 
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I'< bl 4 I Ti . I d a e . na urat10n m mmutes an d 7 . -pomt nausea ratmg score m rae ets per su Jject an dd rug treatment. 
SUBJECT/ DRUG PLACEBO PROM+CAF MEC DIM CHL SCOP+DEX PROM+DEX 
1 23 (6) 16(6) 20 (6) 35 (6) 22 (6) 60 (3) 60 (0) 
2 60 (4) 60 (0) 60 (4) 60 (3) 60 (1) 60 (0) 60 (2) 
3 60 (3 .5) 60 (2.5) 60 (3) 60 (3) 60 (2) 60 (2.5) 60 (2) 
4 39 (6) 14 (6) 60 (2) 44 (6) 60 (5.5) 60 (0) 29 (6) 
5 60 (5) 60 (5) 60 (3) 60 (4) 60 (5) 60 (4) 50 (6) 
6 60 (4) 60 (5) 60 (2) 60 (1) 60 (1) 60 (3) 60 (1 ) 
7 52 (6) 60 (2) 60 (2) 60 (0) 60 (2) 60 (2) 60 (2) 
8 22 (6) 60 (0) 22 (6) 20 (6) 60 (1) 18 (6) 60 (5) 
9 51 (6) 60 (5) 60 (4) 60 (5 .5) 48 (6) 43 (6) 60 (4) 
10 56 (6) 60 (5) 60 (3) 60 (2) 60 (4) 60 (3) 60 (5.5) 
11 60 (5.5) 60 (1) 60 (5 .5) 46 (6) 45 (6) 60 (0) 37 (6) 
12 33 (6) 43 (6) 25 (6) 60 (5.5) 38 (6) 36 (6) 60 (5) 
13 60 (5) 60 (4) 60 (3.5) 60 (1.5) 60 (5) 60 (3) 60 (3) 
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T, bl 4 2 T, . I d I . b t. a e . na ura 10n JY rea men . 
Mean SD % Change from 
(min) (min) CV(%) Placebo RANK 
Placebo 48.95 14.62 29.87 
Prom + Caf 50.94 16.96 33.29 4.07 6 
Mec 51.29 16.59 32.35 4.78 5 
Dim 52.78 12.66 23.99 7.82 4 
Chi 53.28 12.01 22.54 8.85 3 
Scop + Dex 53.61 13.22 24.66 9.52 2 
Prom + Dex 55.85 10.29 18.42 14.10 1 
4.2.2 Subjective Rating of Symptoms of Motion Sickness 
4.2.2.1 7-Point Nausea Rating 
A repeated measures ANOVA was used to test the highest subjective rating based on the 
Golding-Kergeulen 7-Point nausea rating scale per treatment (refer to Table 3.3). The 
results of the ANOV A indicated there was a significant difference (F6,12=4.533;p=.034). 
The mean scale score of the Placebo trial was significantly different from all other 
treatment conditions. These data are reported in Table 4.3. 
T, bl 4 3 7 b a e -pomt nausea ra/mf!. sea e scores JY treatment. 
Mean SD cv % Change from 
(NR) (NR) (%) Placebo RANK 
Placebo 5.31 0.93 17.42 
Prom + Caf 3.65 2.27 62.11 -31.26 2 
Mec 3.85 1.56 40.52 -27.50 5 
Dim 3.81 2. 19 57.35 -28.25 4 
Chi 3.88 2.14 55.21 -26.93 6 
Scop + Dex 2.96 2.17 73.14 -44.26 1 
Prom + Dex 3.65 2. 10 57.40 -31.26 2 
4.2.2.2 Graybiel Score of Motion Sickness 
Pre- and post-motion Graybiel Scores were collected from each participant for each trial 
(refer to Table 3.4). Results from the ANOVA indicated there were no change in the 
difference scores across drug treatments (F6, 12=1.428;p=.324). These data are reported in 
Table 4.4. 
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~ bl 4 4 M G b . I b a e . ean rayl re scores JY treatment. 
% Change from 
Mean SD cv Placebo RANK 
Placebo 9.15 4.51 49.25 
Prom+ Caf 6.15 4.4I 71.76 -32.79 2 
Mec 8.00 4.85 60.60 -I2.57 6 
Dim 7.08 5.52 77.90 -22.62 3 
Chi 7.08 4.96 70.03 -22.62 3 
Scop + Dex 4.69 4.15 88.51 -48.74 I 
Prom + Dex 7.I5 5.06 70.83 -21.86 5 
Results of the Graybiel scores normalized to the trial duration per treatment are presented 
in Table 4.4. The ANOV A reported no significant difference between the normalized 
scores (F6,12=1.156;p=.422). 
~ bl 4 5 G b . I r d a e rayt re scores norma rze . I d . b to Ina ural ron JY treatment. 
% Change from 
Mean SD cv Placebo RANK 
Placebo 0.23 0.16 69.57 
Prom + Caf O.I8 0.23 127.78 -21.74 4 
Mec 0.23 0.27 117.39 0.00 6 
Dim O.I8 0.20 lll.ll -21.74 4 
Chi 0.16 0.15 93 .75 -30.43 3 
Scop + Dex O.I2 O.I6 133.33 -47.83 I 
Prom + Dex O.I5 O.I4 93.33 -34.78 2 
4.3 Physiological Parameters 
Physiological parameters were analyzed for 2 distinct periods, the no-motion baseline and 
the subsequent simulator motion periods. The mean value for the last minute of each of 
these periods was calculated and tested for significance. 
4.3.1 Core Temperature 
Core temperatures were collected during baseline period for each trial. Statistical analysis 
revealed no differences between the core temperature per treatment during baseline 
CF6,I2=0.655;p=.689). These data are reported in Table 4.6. 
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r, bt 4 6 B r b a e ase me core temperature 'Y treatment. 
Mean SD cv % Change from 
(OC) (OC) (%) Placebo RANK 
Placebo 38.34 1.53 3.98 
Prom + Caf 37.78 0.96 2 .55 -1.45 2 
Mec 38.21 1.05 2.75 -0.35 4 
Dim 38.41 1.36 3.53 0.18 5 
Chi 37.16 0.42 1.13 -3 .07 6 
Scop + Dex 38.27 1.20 3. 14 -0.19 3 
Prom + Dex 38.75 1.13 2.92 1.07 I 
The ANOVA indicated no significant difference between core temperatures at the time of 
termination of the trial (F6,12=0.573;p=.743). Data are reported in Table 4.7. 
r, bl 4 7 r, . I b a e na core temperature JY treatment. 
Mean SD cv % Change from 
(OC) (OC) (%) Placebo RANK 
Placebo 37.87 1.51 3.99 
Prom + Caf 37.71 1.08 2.86 -0.42 5 
Mec 38.02 1.05 2.76 0.40 4 
Dim 38.41 1.45 3.79 1.42 2 
Chi 36.98 0.73 1.97 -2.35 6 
Scop + Dex 38.23 1.16 3.02 0.96 3 
Prom + Dex 38.64 1.17 3.03 2.04 I 
The difference between the core temperature at point of motion termination and the 
baseline core temperature was calculated and tested using an ANOV A. The results of the 
ANOV A reported no significant change in the difference scores across treatments 
(F6,12=0.872;p=.558). These data are reported in Table 4.8. 
Table 4.8: Difference between end of trial and baseline core temperature by treatment. 
Mean SD cv % Change from 
(OC) (OC) (%) Placebo RANK 
Placebo -0.47 0.89 190.58 
Prom + Caf -0.07 0.21 300.02 -84.75 4 
Mec -0.19 0.12 66.81 -60.06 1 
Dim 0.00 0.31 593 .89 -100.08 6 
Chi -0.18 0.55 300.91 -60.74 2 
Scop + Dex -0.03 0.14 402.43 -92.57 5 
Prom + Dex -0.11 0.50 454.35 -76.52 3 
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4.3.2 Skin Temperature 
The mean skin temperature was calculated using a weighting equation developed by 
Hardy and Dubois (1938). The ANOVA reported no significant differences in mean skin 
temperatures between treatments at baseline (F6,12=0.992;p=.51 0). These data are 
reported in Table 4.9. 
r, bl 4 9 B r k . b a e . ase me s m temperature JY treatment. 
Mean SD cv % Change from 
(OC) 
_ec) (%) Placebo RANK 
Placebo 27.77 2.17 7.81 
Prom + Caf 28.36 1.37 4.83 2.12 5 
Mec 28.1 2.14 7.62 1.19 3 
Dim 28.43 1.83 6.44 2.38 6 
Chl 28.26 2.07 7.32 1.76 4 
Scop + Dex 27.31 1.97 7.21 -1.66 2 
Prom + Dex 27.28 2.51 9.20 -1.76 1 
The weighted mean skin temperature during the last minute of the motion exposure 
period was tested using a one-way ANOV A. The statistical test reported no significant 
difference (F6,12=2.030;p=.l88). These data are reported in Table 4.10. 
T, bl 4 1 0 T. . I k . b a e . na s m temperature JY treatment. 
Mean SD cv % Change from 
(OC) (OC) (%) Placebo RANK 
Placebo 26.13 2.25 8.61 
Prom + Caf 26.89 1.60 5.95 2.91 6 
Mec 26.7 1.97 7.38 2.18 5 
Dim 26.39 2.14 8.11 1.00 4 
Chi 25.76 2.2 1 8.58 -1.42 3 
Scop + Dex 25.59 2.40 9.38 -2.07 2 
Prom + Dex 25.06 2.54 10.14 -4.09 I 
The difference between end of the motion exposure period and baseline weighted mean 
skin temperature was calculated and tested by an ANOVA. There was no significant 
difference reported (F6,12=2.237;p=.l58). These data are reported in Table 4.11. 
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Table 4.11: Difference between trial end and baseline skin temperature by treatment. 
Mean SD cv % Change from 
(OC) (OC) (%) Placebo RANK 
Placebo -1.64 0.90 54.88 
Prom+ Caf -1.47 0.77 52.38 10.37 5 
Mec -1.4 0.95 67.86 14.63 6 
Dim -2.03 0.67 33.00 23.78 3 
Chi -2.5 1 1.22 48.61 53.05 I 
Scop + Dex -1.73 1.41 81.50 5.49 4 
Prom + Dex -2.22 0.89 40.09 35.37 2 
Skin temperatures, normalized to trial duration, between treatments were tested using an 
ANOVA (F6,I2=3.456;p=.065). These data are presented in Table 4.12. 
T, bl 4 12 M r d k . b a e ean norma tze s tn temperature JY treatment. 
Mean SD cv % Change from 
Table 4.11 (°C/min) COC/min) (%) Placebo RANK 
Placebo -0.04 0.02 50.00 
Prom + Caf -0.03 0.01 33.33 -25.00 3 
Mec -0.03 0.02 66.67 -25.00 3 
Dim -0.04 0.02 50.00 0.00 2 
Chi -0.05 0.02 40.00 25.00 1 
Scop + Dex -0.03 0.02 66.67 -25.00 3 
Prom + Dex -0.04 0.01 25.00 0.00 2 
4.3.3 Galvanic Skin Response 
Galvanic Skin Response data were collected and analyzed. Results were inconclusive, 
due to the fact that the data were likely corrupted because the GSR unit was employed in 
an air-conditioned cabin. Subjects complained of finger numbness caused by the 
coldness of the metal fingertip electrodes. The investigator assured that the numbness 
was not due to an inappropriately applied finger strap. 
4.3 SUSOPS Scores 
SUSOPS tests were performed during the first 3 minutes of baseline and at ten-minute 
intervals during each trial, starting at the 7th minute of motion exposure (See Figure 3.4). 
Statistical analysis of these data compares effect of the drug on each SUSOPS test 
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measurement interval ( eg: SUSOPS scores during the placebo condition at baseline, at 
time 1, etc). 
4.3.1 Logical Reasoning Task (LRT) 
4.3.1.1 LRT Response Time 
LRT average response times were collected for each trial. A repeated measures ANOVA 
was conducted to analyze the response time scores. The statistical test reported no 
significant differences between the SUSOPS measurement intervals for each drug 
treatment (F6,12=2.254;p=.482). Data are reported in Table 4.13. 
T, bl 413 LRT a e . average response t1me. 
% Change from 
Drug Time Mean (ms) Std. Error cv Placebo 
PLACEBO Baseline 4319.18 649.04 15.03 
Final 3757.34 279.29 7.43 13.01 
MEC Baseline 3606.80 451.60 12.52 
Final 3538.57 357.83 I 0.11 1.89 
CHL Baseline 3511.36 265.91 7.57 
Final 3725.46 317.52 8.52 6.10 
DIM Baseline 3619.89 382.91 10.58 
Final 4211.81 760.65 18.06 16.35 
PROM+DEX. Baseline 3995.94 497.80 12.46 
Final 3670.11 240.20 6.54 8.15 
PROM + CAF. Baseline 3794.80 347.00 9.14 
Final 3833.99 297.55 7.76 1.03 
SCOP + DEX. Baseline 3383.47 259.93 7.68 
Final 3393.32 319.43 9.41 0.29 
4.3.1.2 LRT Frequency and Accuracy 
An ANOVA was used to analyze the response frequency (number of attempts) of the 
LRT task. No significant differences were found between the SUSOPS measurement 
intervals for each drug treatment (F6,12=1.299;p=.602). The data are reported in Table 
4.15. 
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Table 4.14: LRT response frequency. 
% Change from 
Drug Time Mean Std. Error cv Placebo 
PLACEBO Baseline 15.00 1.65 11 .02 
Final 15.69 1.32 8.40 4.62 
MEC Baseline 17.08 1.58 9.25 
Final 17.42 1.62 9.32 1.99 
CHL Baseline 17.00 1.33 7.80 
Final 16.15 1.37 8.46 -4.98 
DIM Baseline 17.15 1.75 10.18 
Final 15.77 1.89 12.00 8.07 
PROM + DEX. Baseline 15.3 I 1.21 7.88 
Final 15.54 1.13 7.27 1.51 
PROM + CAF. Baseline 15.85 1.44 9.12 
Final 15.09 1.43 9.50 4.77 
SCOP + DEX Baseline 18.31 1.42 7.76 
Final 18.25 1.59 8.73 0.32 
The number of correct responses in each trial was calculated and tested by an ANOVA. 
The statistical test reported no significant differences between the SUSOPS measurement 
intervals for each drug treatment (F6, 12=.607;p=.776). The data are reported in Table 4.16. 
T, b/ 4 15 LRT a e correct responses. 
% Change from 
Drug Time Mean Std. Error cv Placebo 
PLACEBO Baseline 0.78 0.07 9.54 
Final 0.84 0.05 6.54 6.85 
MEC Baseline 0.84 0.04 5.29 
Final 0.88 0.06 7.23 4.76 
CHL Baseline 0.93 0.03 3.35 
Final 0.92 0.03 3.18 1.32 
DIM Baseline 0.89 0.05 5.78 
Final 0.91 0.04 3.95 1.82 
PROM + DEX. Baseline 0.87 0.05 5.69 
Final 0.88 0.04 4.46 1.82 
PROM +CAF. Baseline 0.86 0.06 6.87 
Final 0.96 0.02 2.36 11 .58 
SCOP + DEX. Baseline 0.85 0.06 6.59 
Final 0.93 0.03 3.21 8.57 
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4.3.2 Serial Subtraction Task (SUB) 
4.3.2.1 SUB Response Time 
A repeated measure ANOVA was used to test the SUB task response time scores. No 
significant differences were found between the SUSOPS measurement intervals for each 
drug treatment (F6,12=.445;p=.840). The data are reported in Table 4.17. 
1'< bl 416 SUB a e average response tme. 
% Change from 
Drug_ Time Mean (ms) Std. Error cv Baseline 
PLACEBO Baseline 5737.21 772.24 13.46 
Final 6060.72 848.70 14.00 5.64 
MEC Baseline 5004.63 673.77 13.46 
Final 5157.19 445.81 8.64 3.05 
CHL Baseline 7490.04 11 48.87 15.34 
Final 6928.81 1110.78 16.03 7.49 
DIM Baseline 5829.93 908.02 15.58 
Final 5869.88 868.07 14.79 0.69 
PROM + DEX. Baseline 5473.59 722.67 13.20 
Final 5596.15 722.65 12.91 2.24 
PROM + CAF. Baseline 4967.09 563 .71 11.35 
Final 5665.17 898.98 15.87 14.05 
SCOP + DEX. Baseline 5486.57 695.94 12.68 
Final 5033.08 472.87 9.40 8.27 
4.3.2.2 SUB Frequency and Accuracy 
A one-way repeated measures ANOVA was used to statistically analyze the frequency of 
response data. The statistical test reported no significant differences between the 
SUSOPS measurement intervals for each drug treatment (F6,Jz=.615;p=.773). The data 
are reported in Table 4.19. 
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Table 4.17: SUB frequency of response. 
Mean(# % Change from 
Drug Time responses) Std. Error cv Baseline 
PLACEBO Baseline 12.08 1.63 13.50 
Final 11 .54 1.71 14.84 4.46 
MEC Baseline 13.85 1.54 11.12 
Final 12.83 1.33 10.36 7.31 
CHL Baseline 10.23 1.17 11.46 
Final 10.77 1.74 16.19 5.26 
DIM Baseline 11.23 1.65 14.72 
Final 12.00 1.54 12.80 6.85 
PROM + DEX. Baseline 13.38 1.95 14.57 
Final 11 .69 1.36 11.64 12.65 
PROM + CAF. Baseline 12.77 1.61 12.58 
Final 13.00 1.52 11 .72 1.81 
SCOP + DEX. Baseline 11.77 1.66 14. 11 
Final 11.92 1.05 8.78 1.31 
Analysis of the correct responses from the SUB tasks by ANOV A reported no significant 
differences between the SUSOPS measurement intervals for each drug treatment 
(F6,12=3.160;p=.416). The data are reported in Table 4.20. 
T, bl 4 18 SUB a e correct responses 
% Change from 
Drug Time Mean Std. Error cv Baseline 
PLACEBO Baseline 0.71 0.11 14.84 
Final 0.75 0.08 11.15 5.21 
MEC Baseline 0.53 0.13 23 .77 
Final 0.53 0.11 20.87 0.39 
CHL Baseline 0.78 0.09 11.46 
Final 0.45 0.11 24.52 42.50 
DIM Baseline 0.69 0. 11 15.84 
Final 0.50 0.11 22.80 28.34 
PROM + DEX. Baseline 0.58 0.11 19.19 
Final 0.48 0.11 2 1.91 17.03 
PROM + CAF. Baseline 0.78 0.09 11 .64 
Final 0.64 0.10 15.3 1 17.56 
SCOP + DEX. Baseline 0.51 0.11 2 1.56 
Final 0.70 0.10 .14.75 37.77 
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4.3.3 Serial Reaction Time (SRT) 
4.3.3.1 SRT Reaction Time 
The one-way repeated measures ANOV A analysis of the average reaction time during the 
SRT task reported no significant differences between the SUSOPS measurement intervals 
for each drug treatment (F6,12=.260;p=.926). The data are reported in Table 4.21. 
T, bl 419 SRT a e . average reactwn tzme. 
% Change from 
Drug Time Mean (ms) Std. Error cv Baseline 
PLACEBO Baseline 697.64 32.86 4.71 
Final 742.20 52.87 7. 12 6.39 
MEC Baseline 679.26 35.73 5.26 
Final 668.15 29.16 4.36 1.64 
CHL Baseline 660.94 19.60 2.96 
Final 682.50 23.66 3.47 3.26 
DIM Baseline 656.74 24.16 3.68 
Final 717.57 41.08 5.73 9.26 
PROM + DEX. Baseline 672.17 26.55 3.95 
Final 688.31 22.10 3.2 1 2.40 
PROM + CAF. Baseline 657.72 24.46 3.72 
Final 698.58 31.53 4.51 6.21 
SCOP + DEX. Baseline 672.58 29.69 4.41 
Final 662.80 25.58 3.86 1.45 
4.3.3.2 SRT Frequency and Accuracy 
Frequency scores of the SRT task were tested using an ANOVA. The statistical test 
reported no significant differences between the SUSOPS measurement intervals for each 
drug treatment (F6,12=082;p=.996). The data are reported in Table 4.23. 
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Table 4.20: SRT frequency scores. 
% Change from 
Drug Time Mean Std. Error cv Baseline 
PLACEBO Baseline 73.62 2.75 3.74 
Final 69.77 3.25 4.66 5.22 
MEC Baseline 76.15 2.82 3.71 
Final 75.58 2.80 3.71 0.75 
CHL Baseline 76.38 1.94 2.54 
Final 72.69 2.14 2.94 4.83 
DIM Baseline 76.23 2.45 3.21 
Final 72.08 3.37 4.67 5.45 
PROM + DEX. Baseline 75.08 2.55 3.39 
Final 72.62 1.87 2.58 3.28 
PROM +CAF. Baseline 77.23 2.88 3.73 
Final 71.82 2.61 3.64 7.01 
SCOP + DEX. Baseline 76.15 2.33 3.06 
Final 75.33 2.34 3.10 1.08 
Statistical analysis companng the correct responses on the SRT task reported no 
significant differences between the SUSOPS measurement intervals for each drug 
treatment (F6,12 =1.853;p=.523). The data are reported in Table 4.24. 
T, bl 4 21 SRT a e correc responses 
% Change from 
Drug Time Mean Std. Error cv Baseline 
PLACEBO Baseline 0.99 0.00 0.23 
Final 0.99 0.00 0.32 0.08 
MEC Baseline 1.00 0.00 0.17 
Final 0.99 0 .00 0.26 0.44 
CHL Baseline 0.99 0.00 0.24 
Final 0.99 0.00 0.32 0.12 
DIM Baseline 0.99 0.00 0.34 
Final 0.99 0.01 0.52 0.37 
PROM + DEX. Baseline 1.00 0.00 0.24 
Final 0.99 0.00 0.36 0.53 
PROM + CAF. Baseline 0.99 0.00 0.26 
Final 0.99 0.00 0.39 0.61 
SCOP + DEX. Baseline 1.00 0.00 0.15 
Final 0.99 0.00 0.26 0 .57 
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5.0 DISCUSSION 
5.1 Introduction 
This research evaluated a range of drugs belonging to different pharmacological classes 
that are known to show varying degrees of effectiveness for symptom remediation among 
individuals who are susceptible to motion sickness. All anti-motion sickness drugs 
employed in this study are available for use with prescriptions and they belong to the 
following pharmacological classes: antihistamines, anticholinergics and antiemetics 
(Personal Communication, Dr. Bob Cheung). 
The interpretation of these data are based on subject responses and, discussion of 
pharmacokinetic outcomes are beyond the scope of this analysis. Implications of the 
findings of this work will provide guidance to persons working in motion rich 
environments who cannot afford to lose vigilance or physical capacity while performing 
their job. 
Statistical analysis reported non-significant differences between the drugs on each of the 
variables tested. This lack of significance may be attributed to the small sample size 
(n= 13), a potential habituation to motion (despite a one-week washout between trials) and 
all drug interventions, except for the placebo, have known, documented mediating effects 
for motion sickness, thus, from the onset, minimizing any potential to detect inter-trial 
differences. 
A lack of statistical significance does not translate into a lack of important findings. 
While not statistically significant, there were similarities in the placebo trial compared to 
the trials where drugs were ingested. While one may not anticipate measureable 
differences between the trials where drugs were used, it was expected that these would be 
different to the placebo trial. 
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While, in most cases, no significant differences were detected, the data were further 
scrutinized using a ranking approach. This qualitative approach was considered to assess 
whether there were similarities between the drug effects and the placebo condition. 
In this respect, the drugs could be evaluated in terms of relative effectiveness on 
physiological parameters, psychomotor performance, and psychophysical reports of 
motion sickness. 
5.2 Duration of Trial 
The duration of the trials varied based on three criteria that determined end-point. 
Subjective nausea rating reached six (voluntary withdrawal), the trial terminated at 60 
minutes, or core body temperature reached 35°C. There were no instances where a 
participant was required to terminate due to loss of core body temperature to 35°C. Thus, 
trial duration was determined by the participant's tolerance to the motion exposure. 
As anticipated, the Placebo trials were terminated earliest. Prom + Dex and Scop + Dex 
were ranked number one and two respectively, with the two greatest percent change from 
placebo (Table 4.2). A study by Wood and Graybiel (1968) evaluated 16 formulations of 
anti-motion sickness drug formulations in the Pensacola Slow Rotation room and required 
the participants to perform head movements to elicit a provocative sensory conflict. 
Scopolamine + Amphetamine were tested in various dosages in combination and alone. 
No formulations were the same as employed in this study, however, it was found that the 
combination of the two increased tolerance to provocative motion by almost 200% over 
the average number of head movements during placebo trials. Wood et al. (1965) reported 
similar findings using the same protocol to test the ability of a selection of drugs to 
mediate motion sickness development. Oral Scopolamine was again validated as a 
successful treatment for motion sickness prevention in a study by Graybiel et al. (1976), 
which ranked second to Promethazine + Ephedrine. As reported in the study by Wood 
and Graybiel (1968) the addition of a stimulant may increase tolerance to provocative 
motion as it reduces the drowsiness effect of the drug. While in some past studies the 
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addition of a stimulant improved motion tolerance and performance, the anecdotal data 
collected during these trials indicated some of the participants felt increased anxiety and 
nervousness, which reduced their comfort during the motion exposure. 
5.3 Subjective Rating of Symptoms of Motion Sickness 
It was expected that the six drugs employed in this study would have a positive 
improvement on the subject's tolerance to motion exposure. The 7-Point Nausea Rating 
scale and Graybiel Score were the criteria used to measure motion sickness symptom 
development. Drug intervention would be expected to ameliorate symptom development 
or prevent the onset of motion sickness, thus increasing trial duration. Overall, Scop + 
Dex and Prom + Caf were ranked one and two respectively (see Tables 4.2, 4.3, 4.4 and 
4.5) as most effective in preventing or mediating the development of motion sickness 
symptoms, Prom + Dex ranked third best at mediating symptoms of motion sickness. 
The results of the subjective rating of motion sickness symptoms data are very similar to 
those of the trial duration, as they reflect the ability of the drugs to mediate motion 
sickness symptoms and improve subject' s tolerance to provocative motion. 
Promethazine and Scopolamine with the addition of a stimulant prove in this study to best 
mediate symptom development and experience. 
5.4 Physiological Measures 
5.4.1Core Temperature 
The range of core temperatures seemed to be quite varied and perhaps not within 
expected physiological ranges. While this may be due to the ingestion of the 
pharmaceuticals, this variability may be a result of equipment calibration issues. This 
variability will likely influence the results of the statistical analyses. 
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The subject's core body temperature was not significantly affected by the exposure to 
cold as the stimulus was 1 ooc and the exposure was of variable duration, from 20-60 
minutes, and likely not strong enough to elicit a decrement in core body temperature. 
This was reflected in the statistical analysis. No statistical differences were revealed, 
however, there may have been practical differences between the treatment conditions, 
Prom+ Dex and Mec were ranked one and two respectively (see Tables 4.6, 4.7 and 4.8) 
as most effective in preserving core body temperature. For the purpose of recommending 
these drugs to individuals who are in occupations that require them to be exposed to 
extreme temperatures, Prom + Dex should be recommended with caution as 
Promethazine affects thermoregulation (Canadian Pharmaceuticals Association, 2007). 
The concept that a drug intervention might affect or facilitate the cooling of motion 
sickness sufferers who are exposed to cold environments while developing or suffering 
from motion sickness is novel. There have been reports of motion sickness having a 
potentiating effect upon individual cooling during immersion in water post-motion 
sickness provocation (Mekjavic et al., 200 I). Findings were similar in two separate 
protocols that provoked motion sickness using a human centrifuge and immersing 
subjects in a 28°C bath (Mekjavic et al., 2001), and a protocol that provoked motion 
sickness using a rotation chair and immersion in a l5°C bath (Nobel et al. , 2003). Each 
experiment required the subjects take a 1 0-minute rest between motion sickness 
provocation and immersion. Each study reported significant decreases m core 
temperature in the immersion trials compared to the control trials. The present study 
varies in that the cold stimulus is less potent, as water conducts heat from the body at 
twenty three times the rate of air (Smith and Hanna, 1975). While the change in core 
temperature found in this study is not significant, given a stronger cold stimulus subjects 
may be at risk of greater heat loss during motion sickness development. 
5.4.2 Skin Temperature 
Similar to the core temperatures, the variability of these measurements is larger than 
expected. As explained above this may be due to equipment calibration Issues, 
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physiological response to the ingested pharmaceuticals or exposure to the cold cabin 
temperatures. 
Skin temperature was expected to decrease as the subjects were wearing sparse clothing, 
and the cabin temperature (1 0°C) was cold enough to elicit a peripheral vasomotor 
response. Prom+ Dex and Chl were ranked one and two overall respectively (see Tables 
4.9-4.12) as with these treatments subjects maintained higher surface skin temperatures. 
Scop + Dex was ranked as third most effective in preserving skin temperature. 
There is little research that explores the effect of motion sickness on skin temperature in 
cold environments. A study by Barcroft and Edholm (1946) that evaluated forearm and 
calf cooling in air and water supports that prolonged exposures to air temperatures of 
under 20°C will result in skin cooling at increased rates at lower temperatures. A study by 
Cheung and Hofer (200 1) reported increased blood flow to the forearm when subjects 
were exposed to Coriolis stimulation. The effect of increased peripheral blood flow 
elicited by provocative motion coupled with a cold environment may result in more rapid 
skin cooling. Drug interventions that mediate motion sickness symptoms may aide in the 
preservation of skin temperature; however, in a cold environment peripheral blood flow 
may be reduced when motion sickness symptoms are mediated. Skin temperature may 
decrease more, or at a faster rate in a cold environment as peripheral vasoconstriction 
would occur to preserve core temperature. In conditions where peripheral blood flow 
remains elevated it could be expected that motion sickness symptoms are stronger, and 
thus symptomatic sweating would result in skin temperatures remaining elevated and well 
perfused. 
5.5 Psychomotor Measures 
5.5.1 Cognitive Measures 
The drugs all had the effect of drowsiness; however, those with dexamphetamine or 
caffeine added to the formulation to counteract the drowsiness effect were expected to 
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improve performance during the psychomotor tasks. Motion sickness and performance 
have been shown to have a negative relationship in past research (Comperatore and 
Rivera, 1998). Studies have also suggested that task performance during motion may 
improve tolerance to motion (Bos et al., 2005). 
This study employed a SUSOPS task battery to measure how motion sickness stress 
affected logical reasoning, reaction/response time and basic math aspects of cognitive 
function, and how treatment conditions affected the same aspects of cognitive abilityChl 
and Scop + Dex ranked as the best overall as they resulted in the best performance on the 
SUSOPS tasks, and Prom + Caf was ranked second best overall performance on the 
SUSOPS task battery. 
5.5.2 Reaction Time 
The most sensitive reaction/response time task was the SRT. The number of responses 
elicited (see Table 4.23) and the response time (see Table 4.21 and 4.22) were the highest 
of the three SUSOPS tasks. There was over one response per second compared to the 
SUB and LRT tasks where response times were three seconds or more. The sensitivity of 
this measure allowed for a better indication of how reaction time was affected during each 
treatment condition. During each treatment condition reaction time between baseline and 
test one was negatively affected by the onset of motion. This was most apparent in the 
SRT task, and not so in the SUB and LRT as they both had much higher response times 
and had a higher degree of task difficulty. In the SRT task, typically administered as the 
final test for each treatment condition, reaction time was closer to that of baseline, most 
likely due to the subject becoming accustomed to the motion stimulus. 
The effect of motion-induced interruptions on cognitive performance appears to be 
under-explored in the literature, and many performance decrements are largely studied, or 
attributed, as the result of motion sickness symptoms. Overall the drugs that most 
effectively preserved cognitive performance were Scop + Dex as the highest ranked and 
Prom + Caf and Mec ranking second. In the SRT task alone, which appeared to give a 
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better indication of reaction time due to the sensitivity of the response time, Prom + Caf 
ranked number one and Scop + Dex and Chl ranked second best. 
5.5.3 Frequency and Accuracy 
Response frequency may indicate the onset of motion sickness symptoms, or the difficulty 
of the task. In the SUB and LRT tasks there were far fewer responses elicited, and 
therefore in this case the task difficulty may be the cause. However, there was some 
variety in the frequency of responses across treatments, while not significant. Mec and 
Scop + Dex were the two drugs that saw the highest number of responses across all tests. 
This is the rank-order seen in the SRT response frequency chart as well (see Table 4.23). 
The drugs that resulted in the highest response frequency were not in alignment with those 
drugs that elicited the highest number of correct responses. Chi, Prom + Caf and Placebo 
were ranked as the three best across all tests in accuracy. This might be due to the 
extreme drowsiness that was experienced on some of the other drugs, or the effect of the 
dexamphetarnine stimulant in the Scopolamine and Promethazine. In the SRT trial Chl 
and Placebo were ranked as the first and second best in terms of accurate responses, 
however, in this test the responses across all drugs were all in the 98%, 99% and 100% 
correct range (see Table 4.24), thus the differences were very minor, and an inaccurate 
response in this test could be due to the motions of the waves and the actual physical 
effects of the motion on the participants ability to place the cursor in the correct position 
and click before being jolted by the ship motions. In both the SUB and the LRT correct 
responses (see Tables 4.20 and 4.16) Prom + Caf was ranked as one to the top two drugs 
in preserving accuracy in more challenging cognitive tasks. Perhaps in terms of accuracy, 
the LRT and SUB task are better representations of how the drugs affect the subjects' 
cognitive ability, as they are measuring basic arithmetic and logical reasoning. 
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6.0 CONCLUSIONS AND RECOMMENDATIONS: 
The mediation of symptoms of motion sickness is critical in occupations requmng 
physical endurance and cognitive vigilance. Traditional pharmaceutical interventions 
will often induce fatigue and provoke other detrimental physiological, perceptual and 
psychomotor changes. 
It was expected that any pharmaceutical intervention intended to mediate positively 
symptoms of motion sickness would have a beneficial effect on prevention of motion 
sickness symptom development and a concomitant positive effect on cognitive 
performance and physiological responses to the cold and motion stimuli. 
After testing the four hypotheses and evaluating the effects of motion sickness and motion 
sickness medications on core body temperature, skin temperature and cognitive 
performance, the conclusion may be drawn that while there was no significant effect 
found, there were several outcomes that are important for many stakeholder groups. This 
section will discuss the drugs best suited to mitigate motion sickness based on the 
desirable or acceptable outcome of using anti-motion sickness to improve tolerance to the 
stimuli. 
This research evaluated a range of drugs belonging to different pharmacological classes 
that are known to mediate symptoms of individuals who are susceptible to motion 
sickness. These drug classes included antihistamines, anticholinergics and antiemetics 
and generally are available by prescription. 
The purpose of this study was to evaluate the ability of each of the six drugs to improve 
the tolerance of susceptible individuals to provocative motions and to assess which drug 
formulations least altered subject's perception, psychomotor and physiological 
performance. Findings of this work will provide guidance to persons working in motion 
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rich environments who cannot afford to lose vigilance or physical capacity while 
performing their job. 
Statistical analysis reported non-significant differences between the drugs on each of the 
variables tested. This lack of significance may be attributed to the small sample size 
(n=13), a potential habituation to motion and that the subjects are being given drugs to 
prevent the development of motion sickness symptoms. However, the experimental 
design, by its nature, limited the likelihood of determining significant differences, 
specifically amongst the treatments that included anti-nauseant medications. In all cases, 
the trend was for the subject to demonstrate the most obvious signs of motion sickness 
under the placebo state. 
Due to the lack of significance the data were analyzed using a rank-order approach. The 
percent change from the placebo condition was calculated for each drug for each variable. 
The larger positive percent change from placebo was ranked as the most "effective" drug. 
The drugs could then be evaluated in terms of effectiveness on physiological parameters, 
psychomotor performance, and psychophysical reports of motion sickness. 
The treatment conditions influenced the various experimental measures differently, and 
thus, the results may be applied to specific scenarios, depending on the desired outcome of 
the drug intervention. Motion sickness symptoms were best mediated by Scop + Dex and 
Prom + Caf, and so would best be applied to scenarios where developing symptoms and 
side-effects from the treatment of motion sickness impairs decision-making ability .. 
Scop + Dex and Prom + Caf were also ranked in the top treatments for maintaining 
baseline cognitive ability under cold and motion stress, and Scop + Dex was also the best 
ranked drug for duration tolerance, so either of these treatments would be best applied in 
scenarios where motion sickness would impede vigilance and occupational performance, 
and prolonged exposure to the stimuli is required. 
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Prom + Dex, Mec and Chi best preserved skin and core temperatures, and Prom + Dex 
was also in the top three treatments that best mediated motions sickness symptoms, and 
duration tolerance. Therefore in these treatments would be best applied in scenarios 
where individuals are exposed to cold climates, however, it should be taken under 
advisement as Promethazine comes with a caution when used in extreme climates 
(Canadian Pharmaceuticals Association, 2007). 
These data suggest that there are trends indicating some drugs are better used in some 
scenarios, such as those requiring cognitive awareness and optimal performance, while 
other drugs may be applied in situations where the main purpose is for the comfort of the 
passenger, or of someone whom vigilance and alertness is not required. 
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Appendix A Call for subjects Poster 
Volunteers are needed for a study that will 
evaluate how body temperatures change with 
exposure to motion and anti-nausea medications. 
0 Contribute to our understanding of how people become sick 
due to motion. 
Who can participate? 
0 Anyone between 19-55 years of age. 
0 Healthy individuals who are not on regular medications 
Who cannot participate? 
0 Females currently pregnant 
0 Anyone with current heart or respiratory illnesses 
To find out more, contact: 
Elizabeth Coady- eacoady@mun.ca or 737-3138 
Patricia Cumby- 778-0304- Centre for Marine Simulation 
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Appendix B Consent To Take Part In Health Research 
January 2006 
Faculty of Medicine, Schools of Nursing and Pharmacy of Memorial 
University of Newfoundland; Eastern Health; Newfoundland Cancer Treatment and 
Research Foundation 
CONSENT TOT AKE PART IN HEALTH RESEARCH 
TITLE: The Effects of Motion Sickness 
INVESTI GA TOR(S): Dr. Scott N. MacKinnon 
SPONSOR: 
You have been invited to take part in a research study. It is up to you to decide whether 
to be in the study or not. Before you decide, you need to understand what the study is 
for, what risks you might take and what benefits you might receive. This consent form 
explains the study. 
The researchers will: 
• discuss the study with you 
• answer your questions 
• keep confidential any information which could identify you personally 
• be available during the study to deal with problems and answer questions 
If you decide not to take part or to leave the study this will not affect your normal 
treatment. 
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1. Introduction/Background: 
The main objective ofthis work is to investigate the effects of selected classes of anti-
motion sickness drugs in suppressing motion sickness induced changes in body 
temperature. 
Findings from this research will likely lead to insights about the mechanisms that 
mediates motion sickness severity and will generate guidance to better inform those who 
operate or train personnel who operate in cold and motion-rich environments. 
2. Purpose of study: 
The purpose of this study is to evaluate the effects of motion sickness on body 
temperature changes. 
3. Description of the study procedures and tests: 
Procedures that will be employed will include responding to questionnaires that 
will evaluate the individual's motion sickness susceptibility, reporting psycho-physical 
responses to the motion stimulus. The participant will be subjected to provocative 
motion, required to ingest an anti-motion sickness drug, or placebo. Temperature 
instrumentation a heart rate monitoring system, including ECG, and an electrodermal 
response system will be utilized to monitor the physiological responses of the 
participant to ensure their safety during the trials. 
4. Length of time: 
The participants will be expected to participate in 5 trials over a five week 
period. The trials will last approximately 1-2 hours each. 
5. Possible risks and discomforts: 
• Insertion of the rectal probe 
• Motion sickness Symptoms (ie: headache, nausea, vomiting) 
• Drowsiness, due to anti-motion medications 
• Cold 
6. Benefits: 
It is not known whether this study will benefit you. 
7. Liability statement: 
Signing this form gives us your consent to be in this study. It tells us that you 
understand the information about the research study. When you sign this form, you do 
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not give up your legal rights. Researchers or agencies involved in this research study still 
have their legal and professional responsibilities. 
8. Confidentiality: 
Participant's identity will be kept confidential. The results will be coded, 
and names will not be associated with trials, drugs or measurements taken. 
9. Questions: 
If you have any questions about taking part in this study, you can meet with the 
investigator who is in charge of the study at this institution. That person is: 
Dr. Scott N. MacKinnon ph:(709) 777-8746 or Elizabeth Coady, ph: 737-3138 
Or you can talk to someone who is not involved with the study at all, but can advise you 
on your rights as a participant in a research study. This person can be reached 
through: 
Office ofthe Human Investigation Committee (HIC) at 709-777-6974 
Email: hic@mun.ca 
73 
Signature Page 
Study title: 
Name of principal investigator: 
To be filled out and signed by the participant: 
Please check as appropriate: 
I have read the consent (and information sheet] . Yes { } No { } 
I have had the opportunity to ask questions/to discuss this study. Yes { } No { } 
I have received satisfactory answers to all of my questions. Yes { } No { } 
I have received enough information about the study. Yes { } No { } 
I have spoken to Dr. and he/she has answered my questions Yes { } No { } 
I understand that I am free to withdraw from the study Yes { } No { } 
• at any time 
• without having to give a reason 
• without affecting my future care [student status, etc.] 
I understand that it is my choice to be in the study and that I may not benefit. Yes { }No{} 
I agree that the study doctor or investigator may read the parts of my hospital. Yes { } No 
records which are relevant to the study. 
I agree to take part in this study. Yes { } No { } 
Signature of participant Date 
Signature of witness Date 
To be signed by the investigator: 
I have explained this study to the best of my ability. I invited questions and gave answers. 
I believe that the participant fully understands what is involved in being in the study, any 
potential risks of the study and that he or she has freely chosen to be in the study. 
Signature of investigator Date 
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Telephone number: 
Appendix C Invasive Procedures Consent Form 
Title: The effect of anti-motion sickness drugs, and physiological responses, 
in a cold and moving environment. 
Rectal Probe: A small plastic tube is inserted through the anus into the rectum and is 
left indwelling for the experiment. Insertion of the probe may result in mild discomfort, 
but since the Subject inserts the probe themselves, this is minimal. Although there is a 
possible risk of perforation of the bowel during insertion (perhaps causing severe 
abdominal inflammation necessitating emergency surgery), the investigator and his 
associates are unaware of this ever having occurred. 
I hereby consent to the procedure above. These 
procedures and their complications have been explained to me to my satisfaction by the 
Investigator, and I have had the opportunity to ask questions both of the Investigator and 
of a physician. 
Volunteer's Signature: _________________ Date: ___ _ _ 
Witness Name: 
--- -------------
Witness Signature: _____ _____ _ Date: 
------
Principal Investigator: Signature: _ _ ________ _ 
Date: 
------ - -
I understand that I shall be given a copy of this consent form. 
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Appendix D Medical History Questionnaire 
Experimental Medical Screening Questionnaire 
Part 1: Personal Information 
Surname: 
Sex (Circle one): Male/Female 
Phone#: 
Given Name: 
Date of Birth: 
Address: 
Part 2: Emergency Contact Information 
Contact Name: Relationship to you: 
Contact Number: 
Part 3: Medical History 
1. Please indicate whether you have now or have ever had a significant episode of 
one or more of the following: 
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Symptom Have Have Symptom Have Have 
Now Had Now Had 
(..J) (..J  (..J) (..J) 
Chest Pain/ Pressure Leg cramps or pain 
Shortness ofbreath Painful,swollen,stiff joints 
Irregular/Rapid heart beat Weakness, numbness, 
tingling in extremities 
Weakness, dizziness, fainting Weight loss or gain 
Wheezing Difficulty sleeping 
Chronic Cough Easily fatigued 
Spitting/Coughing up blood Change in mood 
Hoarseness Loss of memory 
Sore throat Hallucinations 
Difficulty swallowing Heat or cold intolerance 
Nausea/ Vomiting (motion sickness) Heat related illness 
Frequent indigestion Fever, chills, night sweats 
Abdominal cramps or pain Frequent, severe, or 
persistent headaches 
Change in appetite or thirst Persistent swollen glands 
Diarrhea or constipation Change in vision (double 
vision) 
Change in appearance of stool Eye Problems 
List which: 
Bleeding associated with bowel Changes in hearing 
movement (hearing loss, ringing or 
roaring in the ears) 
Transient loss of coordination or of Ear problems 
control of fine movement of hands List which: 
Transient confusion Difficulty clearing ears or 
sinuses in an airplane 
Frequent or painful urination New skin growths 
Incontinence Change in color or shape of 
moles or warts 
Urinary discharge Tendancy to bruise or bleed 
easily or to clot slowly 
Blood in urine Tooth or gum problems 
List which: 
Neck or back pain 
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2a. Indicate whether you have now or have had any of the following conditions: 
Symptom Have Have Symptom Have Have 
Now Had Now Had 
(~) (~) (~) (~) 
Anaemia Hernia 
Asthma HIV/AIDS 
Bell's Palsy Kidney/bladder disease 
(including stones) 
Claustrophobia Pulmonary overpressure 
syndrome/air embolism 
Collapsed lung Rheumatic fever 
Decompression sickness(Bends) Speech, reading, learning 
disorder 
Gout Suicide (thoughts or 
attempts) 
Head injury with unconsciousness or Thyroid disease (goiter) 
memory loss 
Heart murmur Tuberculosis or pleurisy 
Hepatitis (jaundice) Ulcers 
2b. Have you suffered any significant injuries? Yes_ No_ (If no go to question 2c.) 
If Yes indicate what type and approximate date(s): ___________ _ _ 
2c. Have you had any surgical procedures? Yes_ No_ (If no go to question 2d.) 
If Yes indicate which procedures and approximate date(s): _________ _ 
2d. Have you ever fractured a bone(s)? Yes_ No_ (If no go to Question 3.) 
If Yes indicate which bone(s) and approximate date(s) _ _____ _ 
3. Indicate whether you or a family member has or had the following conditions: 
Condition I have 
(~) 
res sure 
Elevated blood cholesterol 
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Someone in my family 
has/had (indicate 
relationshi 
Additional Details 
Heart problems 
Cancer or tumors 
Stroke 
Depression, Schizophrenia, other 
psychiatric problems 
Other significant diseases (indicate) 
Sudden death 
Epilepsy (seizures, fits, convulsions) 
Glaucoma 
Genetic disorders (indicate which) 
4. Have you ever given blood? Yes_ No_ (if No go to Question 5) 
If Yes what was the approximate date of your last donation? _________ _ 
5. Have you been treated in the past year for what you consider a significant condition? 
Yes_ No_ (IfNo go to Question 6) 
If Yes give details: _______________________ _ 
6. Do you have concerns about your fitness to participate in this experiment that you 
would like to discuss with a physician? Yes_ No_ (If no go to Part 4) 
IfYesspecicy: ________________________ __ 
Part 4: Personal Habits 
1. Do you now or have you ever smoked? 
Never smoked _ (go to question 2) 
Current Smoker _ How many years?_ How many cigarettes do you smoke per day? 
Ex-smoker _ Year Quit? __ How many cigarettes per day did you smoke? _ 
2. Do you drink alcohol? Yes_ No_ (If no go to Question 3) 
If yes how many drinks per day? -or- each week? ____ _ 
3a. Do you exercise regularly? Yes_ No_ (If no go to Question 3b.) 
If Yes what type of exercise have you done in the past week? 
How many minutes per day? -or- Per Week? ____ _ 
3b. Do you have any factors that limit your exercise tolerance? Yes_ No_ (if no go to 
Question 3c.) 
IfYesexplrun. _______ _________________ __ 
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Scuba diving 
Flying 
Mountain climbing 
Motor car racing 
Skydiving 
4a. Are you taking any medication at this time (including vitamins and supplements)? 
Yes_ No_ (ifno go to question 4b.) 
If Yes list: 
-----------------------------------------------------
4b. Have you stopped taking any medication in the last 30 days (including vitamins and 
herbal supplements)? Yes_ No_ (IfNo go to question 4c.) 
If Yes list: 
-----------------------------------------------------
4c. Are you allergic to any medication? Yes_ No_ (If No go to question 5) 
IfYes list: 
-----------------------------------------------------
5. Do you wear contact lenses? Yes_ No_ 
6. Are you color blind? Yes_ No_ 
7. Have you had corrective eye surgery? (LASIK/PRK)? Yes_ No_ 
Part 5: For Female Subjects Only 
Section 1: 
Ia. Are you pregnant? Yes_ No_ 
2. Is there a possibility you could be pregnant? Yes No 
Indicate why: ---------------------------------------------
(If there is a possibility you could be pregnant see your physician before continuing) 
3. What was the first day of your last menstrual period? ________________ __ 
Was this period normal for you (duration, flow, etc)? Yes_ No_ 
What is the length of your cycle? __ days. 
Is your cycle regular? Yes_ No_ 
4. Do you have any significant gynecological problems? Yes_ No_ 
If yes provide details: ---------------------------------------------
4. Are you currently breastfeeding? Yes _ No_ 
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Appendix E Motion Sickness Susceptibility Questionnaire 
This questionnaire is designed to find out how susceptible to motion sickness you are 
and what sorts of motion are most effective in causing that sickness. Sickness here means 
feeling queasy or nauseated or actually vomiting. After some background questions, the 
questionnaire consists of two sections: 
Section A is concerned with your childhood experiences of travel and motion sickness, 
that is, before the age of 12. 
Section B is concerned with your experiences of travel and motion sickness over the last 
10 years. 
The correct way to answer each question is explained in the body of the questionnaire. It 
is important that you answer every question. 
Thank you for your participation. 
BACKGROUND QUESTIONS: 
Name: 
-----------------------------------------------------------
1. Please state your age. Years 
------
2. Please state your Sex. Male [] Female [] 
3. Please state you current occupation 
4. Do you regard yourself as susceptible to motion sickness. 
Not at all [] Slightly [] Moderately [ ] Very much so [ ] 
SECTIONS A: Your childhood experience only (before the age of 12). 
For each of the following types of transportation and entertainment please indicate with a 
--1: 
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5. As a child (before the age of 12) how often you traveled or experienced. 
Never 1 to 4 times 5 to 10 11 or more 
times 
Cars 
Buses (Greyhound, GO transit) 
Trains (VIA, GO transit) 
Aircraft 
Small boats Large boats (Ferries/ 
Ocean Liners) 
Swings 
Merry-go-rounds 
Amusement park rides 
6. As a child (before the age of 12) how often you felt sick or nauseated. 
Never Rarely Frequently Always 
Cars 
Buses (Greyhound, GO transit) 
Trains (VIA, GO transit) 
Aircraft 
Small boats Large boats (Ferries/ 
Ocean Liners) 
Swing_s 
Merry-go-rounds 
Amusement park rides 
7. As a child (before the age of 12) how often you vomited. 
Never Rarely Frequently Always 
Cars 
Buses (Greyhound, GO transit) 
Trains (VIA, GO transit) 
Aircraft 
Small boats Large boats (Ferries/ 
Ocean Liners) 
Swings 
Merry-go-rounds 
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.----- ------------------------ - ------·----
I Amusement park rides 
SECTIONS B: Your experience over the last 10 years (approximately). 
For each of the following types of transportation and entertainment please indicate with a 
--.1: 
8 0 h I t 10 vert e as years, h owo ft I d t en you rave e d or expenence . 
Cars 
Buses (Greyhound, GO transit) 
Trains (VIA, GO transit) 
Aircraft 
Small boats Large boats (Ferries/ 
Ocean Liners) 
Swings 
Merry-go-rounds 
Amusement park rides 
9. Over the last 1 0 
Cars 
Aircraft 
Small boats Large boats (Ferries/ 
Ocean Liners) 
Never 1 to 4 times 
Never 
10. Over the last 10 years, how often you vomited. 
Cars 
Buses Greyhound, GO transit) 
Trains VIA, GO transit 
Aircraft 
Small boats Large boats (Ferries/ 
Ocean Liners 
Never Rarel 
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5 to 10 
times 
11 or more 
Thank you for your cooperation. 
Reference: Golding, JF. 1998. Motion sickness susceptibility questionnaire revised and its 
relationship to other forms of sickness. Brain Research Bulletin 47(5):507-16. 
Appendix F Rectal Probe Insertion Instructions and Technical Information 
1. Clean your hands with the hand sanitizer provided. 
2. Obtain the probe assembly in a sealed bag with an alcohol swab and packet of 
lubricant. 
3. Clean the probe with the alcohol swab provided and let the probe dry. 
4. Put a small amount oflubricant on the tip of the probe that will be inserted. 
5. Lift one leg and slowly insert the probe to the small piece of tape that has been 
wrapped around the probe at the 15cm mark. 
6. Tie the horizontal part of the T bandage around your waist at the front. 
7. Bring the vertical part of the T bandage from the waist centre at the back, between 
the legs and tie it to the part of the bandage that is already around the waist. Make 
sure it is snug and will not slip down your body. 
8. Put on your undergarments and clothing. Make sure you direct the connector end 
of the probe out the front waistband of your shorts, so it is accessible. 
9. Clean your hands with the hand sanitizer provided. 
Technical Information: 
The Phillips Esophageal/Rectal Temperature Probe with 400 series Thermistor (Phillips 
Medical Systems Canada, Markham On) consists of an electrically insulated thermistor 
84 
permanently secured within a PVC tube. The thermistor is accurate within ± 0.1 ·c from 
25"C to 45"C. 
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